Disappointment for Alexion over heart drug
The results show that the drug reduced the primary endpoint of combined incidence of nonfatal myocardial infarction (heart attack) or death through 30 days following coronary artery bypass
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.
The American College of Neuropsychopharmacology (ACNP) produced a so-called Task Force Report evaluating the safety and efficacy of selective serotonin reuptake inhibitor (SSRI) antidepressant medication for depressed youths